title: Effectiveness of infliximab in treating selected patients with sarcoidosis.
abstract: OBJECTIVE
  To assess the effectiveness of infliximab (Remicade) in the treatment of patients with sarcoidosis who either do not respond to corticosteroids and other conventional drugs or develop unacceptable side effects to these drugs.
  
  
  METHODS
  A clinical, non-randomized, off-label study.
  
  
  METHODS
  Sarcoidosis clinic at a university teaching hospital.
  
  
  METHODS
  Twelve biopsy-proven sarcoidosis patients, nine women and three men ranging from 45 to 70 years of age with chronic multisystem sarcoidosis refractory to corticosteroids or alternative treatment.
  
  
  METHODS
  Infliximab was infused at a dedicated ambulatory infusion center. The initial dose was 3mg/kg body weight and subsequent doses were given at weeks 2, 4, 6, 10, and 14. All patients received at least six infusions.
  
  
  RESULTS
  All 12 patients improved significantly. One patient had a mild allergic drug reaction that responded to antihistamine. One patient, after 3 months of stopping infliximab treatment, died of a ruptured blood vessel in the abdomen. At autopsy a plasma cell dyscrasia was found.
  
  
  CONCLUSIONS
  Infliximab is safe and effective in treating those patients with multisystem sarcoidosis who are either refractory or develop side effects to a standard regimen of corticosteroids and immunosuppressive agents.
authors.affiliation: Department of Medicine, Pulmonary & Critical Care Division, University of Southern California, 1200N, State St., GNH 11900, Los Angeles, CA 90033, USA.
authors.forename: Samer
authors.initials: S
authors.lastname: Saleh
authors.forename: Shahriar
authors.initials: S
authors.lastname: Ghodsian
authors.forename: Violeta
authors.initials: V
authors.lastname: Yakimova
authors.forename: John
authors.initials: J
authors.lastname: Henderson
authors.forename: Om P
authors.initials: OP
authors.lastname: Sharma
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D012507:Sarcoidosis / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab